Axcella Therapeutics (AXLA) Misses Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Axcella Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
March 30, 2022 7:32 AM EDTCompleted $25 million registered direct stock offering priced at the market Initiated Phase 2a Long COVID clinical trial Fast Track designation received from FDA for AXA1125 in NASH with liver fibrosis Enhanced management team Long COVID top-line data and NASH interim data expected in the third quarter of 2022 Company to host conference call at 8:30 a.m. ET today
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using... More
